×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AUPH – aurinia pharmaceuticals inc - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AUPH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/26
11:42 am
auph
Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Neutral
Report
Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
12/16
04:03 pm
auph
Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms [Seeking Alpha]
Low
Report
Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms [Seeking Alpha]
12/16
10:12 am
auph
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors [Yahoo! Finance]
Low
Report
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors [Yahoo! Finance]
12/16
10:12 am
auph
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors [Globe and Mail, The (Toronto, Canada)]
Low
Report
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors [Globe and Mail, The (Toronto, Canada)]
12/15
03:42 am
auph
Assessing Aurinia Pharmaceuticals After Its 80% 2025 Surge and Lupus Nephritis Momentum [Yahoo! Finance]
Low
Report
Assessing Aurinia Pharmaceuticals After Its 80% 2025 Surge and Lupus Nephritis Momentum [Yahoo! Finance]
12/3
08:05 am
auph
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was given a new $16.00 price target on by analysts at Leerink Partners.
Medium
Report
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was given a new $16.00 price target on by analysts at Leerink Partners.
11/30
06:22 pm
auph
A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation After Recent Share Price Surge [Yahoo! Finance]
Low
Report
A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation After Recent Share Price Surge [Yahoo! Finance]
11/19
04:45 pm
auph
First Look at Roche/Genentech's Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights [Yahoo! Finance]
Low
Report
First Look at Roche/Genentech's Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
BEAT
Report
5.7%
aurinia pharmaceuticals inc - common shares
7/31/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
MISS
Report
-2.6%
aurinia pharmaceuticals inc - common shares
5/12/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
BEAT
Report
-5.1%
aurinia pharmaceuticals inc - common shares
2/27/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
MISS
Report
-4.7%
aurinia pharmaceuticals inc - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/24
05:19 pm
auph
Form 4 Aurinia Pharmaceuticals For: Nov 21 Filed by: Bailey Jeffrey Allen
Low
Report
Form 4 Aurinia Pharmaceuticals For: Nov 21 Filed by: Bailey Jeffrey Allen
11/24
05:18 pm
auph
Form 4 Aurinia Pharmaceuticals For: Nov 21 Filed by: Johnson Craig A
Low
Report
Form 4 Aurinia Pharmaceuticals For: Nov 21 Filed by: Johnson Craig A
11/4
08:01 am
auph
Form 8-K Aurinia Pharmaceuticals For: Nov 04
Medium
Report
Form 8-K Aurinia Pharmaceuticals For: Nov 04
11/4
06:09 am
auph
Form 10-Q Aurinia Pharmaceuticals For: Sep 30
Medium
Report
Form 10-Q Aurinia Pharmaceuticals For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/9
Form SC 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd.
13.5%
12/10 Form 6-K Aurinia Pharmaceuticals For: Dec 10 11.7%
9/9 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is now covered by analysts at Citigroup Inc. They set an "outperform" rating and a $14.00 price target on the stock. 10.3%
11/28 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.8%
12/3 Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference 7.1%
3/19 Form 6-K Aurinia Pharmaceuticals For: Mar 18 6.4%
10/15 Does The Aurinia Pharmaceuticals Inc. (TSE:AUP) Share Price Fall With The Market? [Yahoo! Finance News] 6.1%
4/20 Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors 5.4%
12/4 Form 6-K Aurinia Pharmaceuticals For: Dec 03 4.9%
12/10 Form SC 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd. 4.6%
12/10 Form 6-K Aurinia Pharmaceuticals For: Dec 10 11.7%
9/9 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is now covered by analysts at Citigroup Inc. They set an "outperform" rating and a $14.00 price target on the stock. 10.3%
11/28 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.8%
12/3 Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference 7.1%
3/19 Form 6-K Aurinia Pharmaceuticals For: Mar 18 6.4%
10/15 Does The Aurinia Pharmaceuticals Inc. (TSE:AUP) Share Price Fall With The Market? [Yahoo! Finance News] 6.1%
4/20 Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors 5.4%
12/4 Form 6-K Aurinia Pharmaceuticals For: Dec 03 4.9%
12/10 Form SC 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd. 4.6%
TOP News Decliners
10/10
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating.
-13.4%
3/16 Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis -12.3%
3/5 Aurinia Pharmaceuticals' (AUPH) CEO Peter Greenleaf on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -10.4%
3/11 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.3%
3/12 Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative -6.7%
8/6 Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.6%
2/22 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.3%
3/17 Form 6-K Aurinia Pharmaceuticals For: Mar 17 -5.5%
2/25 Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team -5.4%
12/2 Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit [Yahoo! Finance News] -5.3%
3/16 Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis -12.3%
3/5 Aurinia Pharmaceuticals' (AUPH) CEO Peter Greenleaf on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -10.4%
3/11 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.3%
3/12 Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative -6.7%
8/6 Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.6%
2/22 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.3%
3/17 Form 6-K Aurinia Pharmaceuticals For: Mar 17 -5.5%
2/25 Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team -5.4%
12/2 Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit [Yahoo! Finance News] -5.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: